KR20230124384A - Composition for anti-virus comprising extract from curled dock - Google Patents

Abstract

Regarding the antiviral composition, the antiviral composition according to an embodiment of the present invention includes a CURLED DOCK extract as an active ingredient.

Description

Composition for antiviral containing extracts of sorghum as an active ingredient {COMPOSITION FOR ANTI-VIRUS COMPRISING EXTRACT FROM CURLED DOCK}

The present invention relates to an antiviral composition, and more particularly, to an antiviral composition comprising an active ingredient extracted from a plant.

Coronavirus (CoV) is a virus that can infect humans and various animals, and is an RNA virus with a gene size of 27 to 32 kb. There are four genera (alpha, beta, gamma, and delta) in the family Coronaviridae. Alpha and beta can infect humans and animals, while gamma and delta only infect animals. The shape shows a spherical shape when observed under an electron microscope, as in the name of the corona virus, and the external spike protein is characterized by a crown shape.

Six types of human coronaviruses are known so far. Types that cause the common cold include 229E, OC43, NL63, and HKU1, and types that can cause severe pneumonia include SARS-CoV and MERS-CoV. In addition, the new coronavirus that has occurred since 2019 is SARS-CoV-2, and when infected, it causes various respiratory infections ranging from mild to severe, such as fever, malaise, cough, dyspnea, and pneumonia. In addition, phlegm, sore throat, headache, hemoptysis, nausea, and diarrhea also appear. Korea's first-class infectious disease Emerging infectious disease syndrome, classified as a legal infectious disease, spreads through droplets and contact. The incubation period is 1 to 14 days, and the global fatality rate is about 3.4% (WHO, 3.5 standard), so there is no cure yet.

An object of the present invention is to provide an antiviral pharmaceutical composition comprising a plant extract as an active ingredient.

Another technical problem to be achieved by the present invention is to provide an antiviral skin external preparation comprising a plant extract as an active ingredient.

Another technical problem to be achieved by the present invention is to provide an antiviral health functional food composition comprising a plant extract as an active ingredient.

Another technical problem to be achieved by the present invention is to provide a quasi-drug composition for preventing virus attachment comprising a plant extract as an active ingredient.

In addition, another technical problem to be achieved by the present invention is to provide an antiviral cosmetic composition comprising a plant extract as an active ingredient.

The problem to be solved by the present invention is not limited to the problems mentioned above, and other problems not mentioned will be understood by those skilled in the art from the description below.

According to one embodiment of the present invention, an antiviral pharmaceutical composition comprising an extract of CURLED DOCK as an active ingredient is provided.

The sorghum is a perennial plant belonging to the family Nodeulaceae that is native to Northern Europe and spreads to the Southern Hemisphere and is distributed all over the world. It grows all over Korea, and morphologically similar Chamsorijaeng, Mukbalsorijaeng, and Geumsorijaengi are also distributed. The stem grows straight to 30 to 80 cm and is dark green or sometimes purplish. The leaves from the root are bundled and have a long oval shape with a length of 13 to 30 cm and a width of 4 to 6 cm. The leaves are edible and the roots are used as herbal medicines. The leaves and roots of the rhubarb are called rhubarb leaves or rhubarb, and the roots contain anthraquinons such as emodin, chrysophanol, and nepodin.

In addition, because tannin is rich in sorghum, it expands blood vessels, promotes blood circulation, and inhibits the growth of cancer cells. In addition, it is known to exhibit excellent antibacterial effects against Vibrio vulificus and Saccharomyces cerevisiae, have anti-inflammatory and astringent effects, and suppress symptoms caused by inflammation such as cough, asthma, and periodontitis.

In the present specification, "extract" means a product such as a liquid component obtained by immersing a desired material in various solvents and then extracting at room temperature or at elevated temperature for a certain period of time, or a solid component obtained by removing the solvent from the liquid component. can In addition, in addition to the above results, it can be comprehensively interpreted as including all of the dilutions of the results, their concentrates, their adjusted and purified products, and the like.

The extract may be a sorrel extract, preferably a sorrel root extract. Extraction solvents include purified water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, liquid diluent, ethoxy suspending agents such as sylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tragacanth, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, Sulfosuccinic acid monoesters, isethionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, Nolin derivatives, or ethoxylated glycerol fatty acid esters, alcohols such as glycerin.

Preferably, the extraction solvent may be a polar solvent, a non-polar solvent or a combination thereof. As the polar solvent, water, anhydrous or hydrous alcohol having 1 to 6 carbon atoms (methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol or 2-butoxyethanol, etc.) or It may be an alcoholic compound (ethylene glycol, propylene glycol, or butylene glycol, etc.), acetic acid, dimethyl-formamide (DMFO), dimethyl sulfoxide (DMSO), or a combination thereof, and non-polar solvents include hexane and oroalkane , pentane, hexane, ethyl acetate, methyl acetate, butyl acetate, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1-pentene, 1-chlorobutane, acetone, 1-chloro Pentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, diethyl ether, chlorobenzene, benzene, diethyl ether, diethylsulfide, chloroform, dichloromethane, 1,2- dichloroethane, aniline, diethylamine, ether, carbon tetrachloride, THF or combinations thereof. In the present specification, the extract is not particularly limited thereto, and may include extracts having substantially the same effect prepared using other solvents as well as the solvent.

In one embodiment, the extraction method using the solvent may be performed according to a method known in the art. For example, a cold extraction method in which sorrel is immersed in the solvent and extracted at room temperature of 10 to 25 ° C., a heating extraction method in which extraction is performed by heating at 40 to 100 ° C., a reflux extraction method using a reflux condenser, and ultrasonic waves using an ultrasonic device It can be performed through methods such as an extraction method and a high-frequency extraction method using a high-frequency device.

In one embodiment, the virus may be a corona virus. The coronaviruses include alphacoronavirus, betacoronavirus, gammacoronavirus, deltacoronavirus, human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), and severe acute respiratory syndrome coronavirus (SARS-CoV). ), human coronavirus NL63 (HCoV-NL63, New Haven coronavirus), human coronavirus HKU1, Middle East respiratory syndrome coronavirus (MERS-CoV) or severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2 or 2019 novel coronavirus or 2019-nCoV).

As used herein, "antiviral" means the ability to inhibit the production of coronavirus particles, that is, the ability to effectively inhibit the formation and / or replication of coronaviruses in host cells, especially mammals, including humans. Compositions containing the sorrel extract as an active ingredient may have antiviral effects by interfering with mechanisms necessary for viral infection, replication or proliferation.

The content of the raspberry extract in the above or below composition according to an embodiment is 0.0001 to 100% by weight, 0.001 to 100% by weight, 0.01 to 100% by weight, 0.1 to 100% by weight, 1 to 100% by weight, based on the total composition. 10 to 100% by weight, 0.0001 to 80% by weight, 0.001 to 80% by weight, 0.01 to 80% by weight, 0.1 to 80% by weight, 1 to 80% by weight, 10 to 80% by weight, 0.0001 to 70% by weight, 0.001 to 70 wt%, 0.01 to 70 wt%, 0.1 to 70 wt%, 1 to 70 wt%, 10 to 70 wt%, 0.0001 to 60 wt%, 0.001 to 60 wt%, 0.01 to 60 wt%, 0.1 to 60 wt% %, 1 to 60% by weight, 10 to 60% by weight, 0.0001 to 50% by weight, 0.001 to 50% by weight, 0.01 to 50% by weight, 0.1 to 50% by weight, 1 to 50% by weight, 10 to 50% by weight, 0.0001 to 40% by weight, 0.001 to 40% by weight, 0.01 to 40% by weight, 0.1 to 40% by weight, 1 to 40% by weight, 10 to 40% by weight, 0.0001 to 30% by weight, 0.001 to 30% by weight, 0.01 to 30 wt%, 0.1 to 30 wt%, 1 to 30 wt%, 10 to 30 wt%, 0.0001 to 20 wt%, 0.001 to 20 wt%, 0.01 to 20 wt%, 0.1 to 20 wt%, 1 to 20 wt% %, 10 to 20%, 0.0001 to 10%, 0.001 to 10%, 0.1 to 10% or 1 to 10%. Preferably, it may be 1 to 15% by weight.

In addition, according to an embodiment, the content of the solvent for generating the sorrel extract may be 10 to 100% by weight, preferably 50 to 99% by weight, more preferably 85 to 100% by weight based on the total composition. 99% by weight. Also, in one embodiment, the solvent may be 50 to 100% by weight of ethanol.

The number of administrations of the composition according to one embodiment may be administered in excess of 1 to 3 times per day or as needed. However, the dosage may be variously prescribed depending on factors such as formulation method, administration method, patient's age, weight, sex, medical condition, food, administration time, administration route, excretion rate and reaction sensitivity, and those skilled in the art If so, the dosage can be appropriately adjusted by considering these factors. The number of administrations can be once or twice or more within the range of clinically acceptable side effects, and administration can be performed at one or two or more sites.

For animals other than humans, the same dosage per kg as for humans is used, or the above dosage is converted by, for example, the volume ratio (eg, average value) of the organ (heart, etc.) between the target animal and the human. A single dose can be administered. Possible routes of administration include oral, sublingual, parenteral (eg, subcutaneous, intramuscular, intraarterial, intraperitoneal, intrathecal, or intravenous), rectal, topical (including transdermal), inhalation, and injection, or implantation. It may involve the implantation of devices or substances. Examples of animals to be treated according to one embodiment include humans and other target mammals, specifically humans, monkeys, mice, rats, rabbits, sheep, cows, dogs, horses, pigs, etc. included However, the dosage, number of times, and subjects are not limited to the scope herein.

The pharmaceutical composition according to one embodiment may include a pharmaceutically acceptable carrier and/or additives. For example, sterile water, physiological saline, common buffers (phosphoric acid, citric acid, other organic acids, etc.), stabilizers, salts, antioxidants (ascorbic acid, etc.), surfactants, suspending agents, tonicity agents, or preservatives, etc. can do. For topical administration, it is also possible to combine organic substances such as biopolymers, inorganic substances such as hydroxyapatite, specifically collagen matrices, polylactic acid polymers or copolymers, polyethylene glycol polymers or copolymers, and chemical derivatives thereof. can include

The pharmaceutical composition according to an embodiment, if necessary according to the administration method or formulation, suspending agent, dissolution aid, stabilizer, isotonic agent, preservative, anti-adsorption agent, surfactant, diluent, excipient, pH adjuster, analgesic agent , buffers, reducing agents, antioxidants and the like may be appropriately included. The pharmaceutical composition according to an embodiment is formulated in unit dosage form by using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by those skilled in the art. It can be prepared as, or it can be prepared by inserting into a multi-dose container. The dosage form may be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or in the form of a powder, granule, tablet or capsule.

In addition, it is possible to provide a pharmaceutical preparation for external use for the skin containing the sorrel extract according to another embodiment as an active ingredient. At this time, the meaning of the sorijaeng, extract, virus and antiviral is as described above.

In the present specification, "external application" may be a preparation provided for external use, and the composition for external application for skin may be formulated by containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example solutions, gels, solids, anhydrous pasty products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes) and It may be provided in the form of a non-ionic vesicular dispersion or in the form of a cream, toner, lotion, powder, ointment, spray, pack or conceal stick. It may be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant, but is not limited thereto. These compositions can be prepared according to conventional methods in the art. The composition for external application for skin may have an antiviral effect.

According to another embodiment, it is possible to provide a health functional food composition for antiviral containing an extract of japonica as an active ingredient. At this time, the meaning of the sobster, extract, virus and antiviral is as described above. As used herein, "food" means meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, It may be a vitamin complex, health functional food, health food, etc., and may include all foods in a conventional sense.

The food composition according to one embodiment can be consumed daily, and excellent antiviral effects can be expected, so it can be very useful for health promotion purposes. In this specification, "functional food" is the same term as food for special health use (FoSHU), and medicine processed to efficiently display bioregulatory functions in addition to nutritional supply, It can mean food with high medical effect. Here, 'function (sex)' may mean obtaining useful effects for health purposes such as regulating nutrients for the structure and function of the human body or physiological functions. In the present specification, food can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and ingredients commonly added in the art during the manufacture.

In addition, the formulation of the food may also be prepared without limitation as long as the formulation is recognized as a food. In the present specification, the food composition can be prepared in various types of formulations, and unlike general drugs, there is an advantage that there is no side effect that may occur when taking a drug for a long time using food as a raw material, and it is excellent in portability, The food according to the embodiment can be consumed as an adjuvant to enhance the antiviral effect.

The health food (health food) may mean a food having an active health maintenance or promotion effect compared to general food, health supplement food (health supplement food) may mean a food for the purpose of health supplement. In some cases, the terms health functional food, health food, or health supplement food may be used interchangeably. The health functional food is a food prepared by adding the composition to food materials such as beverages, teas, spices, chewing gum or confectionery, or encapsulated, powdered, or suspended, and when ingested, brings a specific effect on health However, unlike general drugs, there may be an advantage that there is no side effect that may occur when taking a drug for a long time using food as a raw material.

The health functional food composition may further include a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier commonly used in the art may be used. In addition, the health functional food composition may include additional ingredients that are commonly used in food compositions to improve smell, taste, and vision. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, and panthotenic acid may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), and chrome (Cr); and amino acids such as lysine, tryptophan, cysteine and valine.

In addition, the food composition contains preservatives (potassium sorbate, sodium benzoate, salicylic acid and sodium dehydroacetate, etc.), bactericides (bleaching powder, high bleaching powder and sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA) and butylhydroxide). hydroxytoleuene (BHT), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite and sodium nitrite, etc.), bleaching agents (sodium sulfite, etc.), seasonings (MSG and sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin and sodium, etc.), flavoring (vanillin and lactones, etc.), expanding agent (allum and D-potassium hydrogen tartrate, etc.), strengthening agent, emulsifier, thickener (thickening agent), coating agent, gum base agent, foam inhibitor, solvent or improver, etc. May contain food additives. The additive may be selected according to the type of food and used in an appropriate amount.

The food composition according to one embodiment may be a health drink composition. The health beverage composition may contain various flavoring agents or natural carbohydrates as additional components, like conventional beverages. The aforementioned natural carbohydrates include monosaccharides such as glucose and fructose; disaccharides such as maltose and sucrose; polysaccharides such as dextrins and cyclodextrins; It may be a sugar alcohol such as xylitol, sorbitol, or erythritol. Sweeteners include natural sweeteners such as thaumatin and stevia extract; Synthetic sweeteners such as saccharin and aspartame may be used. The ratio of the natural carbohydrates may be 0.01 to 0.04g, specifically about 0.02 to 0.03g per 100ml of the health drink composition of the present invention, but is not limited thereto.

In addition to the above, the health drink composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin and The same humectant, alcohol or carbonating agent may be contained. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages, or vegetable beverages. These components may be used independently or in combination. The ratio of these additives is not very important, but may be selected in the range of 0.01 to 1.0 parts by weight per 100 parts by weight of the health drink composition of the present invention.

Another embodiment is to provide a quasi-drug composition for preventing virus attachment, containing an extract of P. raspberry as an active ingredient. At this time, the meanings of the riddle, the extract, and the virus are as described above. In the present specification, "quasi-drugs" may refer to products whose action is milder than pharmaceuticals among products used for the purpose of diagnosing, treating, improving, mitigating, treating, or preventing human or animal diseases. For example, according to the Pharmaceutical Affairs Act of the Republic of Korea, quasi-drugs are items excluding items used for pharmaceutical purposes, and may include products used for the treatment or prevention of human or animal diseases and products with minor or no direct action on the human body.

The quasi-drug composition may be prepared in a form selected from the group consisting of body cleanser, foam, soap, mask, ointment, cream, lotion, essence and spray, but is not limited thereto. The quasi-drug composition may be added as is or used together with other quasi-drugs or quasi-drug ingredients, and may be appropriately used according to a conventional method.

Another embodiment is to provide an anti-viral cosmetic composition containing a sorrel extract as an active ingredient. At this time, the definitions of the sobster, extract, virus and antivirus are as described above. The cosmetic composition includes solutions, external ointments, creams, foams, nutrient lotions, softening lotions, skin softeners, skin toners, astringents, perfumes, packs, softening water, emulsions, makeup bases, essences, soaps, liquid cleansers, bath additives, and sunscreens. Cream, Sun Oil, Suspension, Emulsion, Paste, Gel, Lotion, Milk Lotion, Moisture Lotion, Nourishing Lotion, Massage Cream, Nourishing Cream, Moisture Cream, Hand Cream, Foundation, Essence, Nourishing Essence, Pack, Powder, Soap, A formulation selected from the group consisting of surfactant-containing cleansing, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, oil, powder foundation, emulsion foundation, wax foundation, patch, mask pack, aerosol, spray and capsule It can be manufactured, but is not limited thereto.

The cosmetic composition of the present invention is harmless to the human body and does not impair the quality of cosmetics due to its addition, so it is suitable for being included in the cosmetic composition. In particular, the sorrel extract of the present invention has no cytotoxicity and exhibits antiviral activity by inhibiting the binding of coronavirus to the ACE-2 receptor expressed on the surface of its host cell. it is desirable

The cosmetic composition may further include one or more cosmetically acceptable carriers formulated in general skin cosmetics, and as typical ingredients, for example, oil, water, surfactants, moisturizers such as glycerin, lower alcohols, and thickeners , A chelating agent, a colorant, a preservative, a flavoring agent, etc. may be appropriately mixed, but is not limited thereto. Cosmetically acceptable carriers included in the cosmetic composition may vary depending on the formulation.

When the formulation of the cosmetic composition is ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, Zinc oxide or mixtures thereof may be used. When the formulation of the cosmetic composition is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or a mixture thereof may be used as a carrier component, and in particular, in the case of a spray, additionally propellants such as chlorofluorohydrocarbons, propane/butane or dimethyl ether. These may be used alone or in combination of two or more.

When the formulation of the present invention is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohard propellants such as, but not limited to, low carbon, propane/butane or dimethyl ether. These may be used alone or in combination of two or more.

When the formulation of the cosmetic composition is a solution or emulsion, a solvent, solubilizing agent or emulsifying agent may be used as a carrier component. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, and 1,3-butyl glycol oil may be used, and in particular, cottonseed oil and peanut oil , corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty esters, polyethylene glycols or fatty acid esters of sorbitan may be used.

When the formulation of the cosmetic composition is a suspension, a liquid diluent such as water, ethanol or propylene glycol, an ethoxylated isostearyl alcohol, a suspension such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester as a carrier component agent, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth, and the like may be used. When the formulation of the cosmetic composition is a capsule, it may be formulated in the form of an alginate capsule, an agar capsule, a gelatin capsule, a wax capsule, or a double capsule. Not limited. In addition, the cosmetic composition includes commonly used adjuvants, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic activators, preservatives, antioxidants, solvents, fragrances, fillers, blocking agents, pigments, odor absorbers and dyes, etc. can include

When the formulation of the present invention is a soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolyzates, isethionates, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugars, etc. may be used as carrier components. It may be, but is not limited thereto. These may be used alone or in combination of two or more.

In the cosmetic composition of the present invention, the raspberry extract may be included in a dry weight, specifically, from 0.0001% to 50% by weight of the total weight of the cosmetic composition, and specifically from 1% to 40% by weight. . There is an advantage of exhibiting excellent antiviral efficacy within the above range, and there is an advantage of stabilizing the formulation of the composition.

According to the embodiments of the present invention, the composition containing the extract of Psoriasis as an active ingredient not only prevents or treats viral infectious diseases through excellent antiviral effects against coronavirus, but also extracts extracted from P. Since stability is recognized by using it, it is possible to provide an antiviral pharmaceutical composition or cosmetic composition that can be usefully used in various industrial fields.

1 and 2 are graphs confirming the antioxidant efficacy of the pharmaceutical composition of the sorrel extract according to an embodiment of the present invention.
3 and 4 are the results of confirming the whitening efficacy of the sorrel extract according to an embodiment of the present invention.
5 is a result showing the anti-wrinkle efficacy of the sorrel extract according to an embodiment of the present invention.
6 is a result of confirming the anti-allergic efficacy of the sorrel extract according to an embodiment of the present invention.
7 and 8 are the results of confirming the antiviral efficacy of the sorrel extract according to an embodiment of the present invention.

Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings.

Embodiments of the present invention to be described below are provided to more clearly explain the present invention to those skilled in the art, and the scope of the present invention is not limited by the following examples, Embodiments may be modified in many different forms.

As used herein, terms of degree such as "about" and "substantially" are used to mean a range of or close to that number or degree, taking into account inherent manufacturing and material tolerances, and are provided to aid understanding of the present disclosure. Exact or absolute figures are used to prevent undue exploitation by an infringer of the stated disclosure.

Hereinafter, the present invention will be described in more detail through examples. Since these examples are intended to illustrate the present invention only, the scope of the present invention is not to be construed as being limited by these examples.

Example 1. Preparation of sorghum extract

To the entire mixture, 85 to 99% by weight of a mixed solvent of 1 to 15% by weight of dried and shredded sorrel raw material, purified water, 10 to 50% butylene glycol, and 2 to 10% glycerin was added and heated to 45 to 80 ° C. Sorijaeng extract was extracted using ceramic, a traditional extraction material used in oriental medicine and oriental medicine, for 6 to 48 hours at a temperature of . Desirably, the raw material for the rascal may be the root of the rascal.

Experimental Example 1. DPPH scavenging activity

The sorrel extract of Example 1 was prepared at 0.1, 0.2, 0.4, and 0.8% concentrations. Thereafter, the extract of each concentration was mixed with 0.2 mM DPPH (1,1-diphenyl-2 picrylhydrazyl radical) reagent per well in a 1: 1 ratio, put into a 96-well plate, reacted at room temperature for 20 minutes, and then used a microplate reader. The absorbance was measured at 517 nm and shown in FIG. 1 .

Referring to FIG. 1, it can be seen that the DPPH scavenging activity also increased as the concentration of the raspberry extract increased, showing the antioxidant activity, and having an SC ₅₀ (50% Scavenging Concentration) value at 0.07%.

Experimental Example 2. Intracellular ROS inhibition

The sorrel extract of Example 1 was prepared at 0.5, 1, and 2% concentrations. In addition, HDFn cells were cultured in a 96-well plate in a 37°C, 5% CO2 incubator for 24 hours, replaced with a new medium after 24 hours, and the prepared extracts for each concentration and the control group without the extract were respectively Administered and incubated for 1 hour. After culturing, it was washed with saline, treated with H ₂ O ₂ and DCFH-DA, left at 37° C. for 30 minutes, and the absorption wavelength at 485 nm and the emission wavelength at 538 nm were measured and shown in FIG. 2 .

Referring to Figure 2, it can be seen that the sorrel extract exhibits an antioxidant effect of 50.5% at a concentration of 2%.

Experimental Example 3. L-DOPA inhibitory activity

The raspberry extract of Example 1 was prepared at concentrations of 0.6, 1.3, 2.5, 5, and 10% and placed in a 96-well plate in 0.1 M sodium phosphate buffer (pH 6.8) and 1,000 units of Tyrosinase extracted from mushrooms. / mL and reacted at 37°C for 3 minutes. Thereafter, 5 mM L-DOPA was injected and absorbance was measured at 475 nm using a microplate reader, as shown in FIG. 3 .

Referring to FIG. 3 , it can be seen that the L-DOPA inhibitory activity was exhibited as the concentration of the sorrel extract increased, and the IC ₅₀ (50% Inhibition Concentration) value was found at 2.8%.

Experimental Example 4. Intracellular melanin content

Figure 4 shows the melanin production inhibitory effect of the sorrel extract of the present invention. The raspberry extract of Example 1 was prepared at concentrations of 0.06, 0.13, and 0.25%, and B16F10 cells were cultured in a 24-well plate in a 37°C, 5% CO2 incubator for 24 hours, and then replaced with a new medium after overnight. and cultured by administering the sorghum extract for each concentration. After 72 hours, the culture medium was removed and treated with 1N NaOH containing 10% DMSO to dissolve intracellular melanin at 60°C. This solution was placed in a 96-well plate and absorbance was measured at 405 nm, which is shown in FIG. 4 .

Referring to FIG. 4 , it can be seen that the whitening effect of the sorrel extract at a concentration of 2% showed a melanin pigment inhibition rate of 13.7%.

Experimental Example 5. Elastase inhibition activity

Figure 5 shows the anti-wrinkle effect of the sorrel extract of the present invention. The sorrel extract of Example 1 was prepared for each concentration of 0.3, 0.6, 1.3, 2.5, and 5.0%. In addition, 1 M Tris-HCl buffer at pH 8.0 and elastase from porcine pancrease (2 units/mL) were mixed in a 96-well plate and reacted at 37°C for 5 minutes. After the reaction, the extract and 1.45 mM STANA for each concentration were injected, and the sample without the extract was reacted at 37 ° C. for 5 minutes, respectively, as a control, and then the absorbance was measured at 405 nm using a microplate reader. 5.

Referring to FIG. 5, it can be seen that the raspberry extract showed elastase inhibitory activity as the concentration of the extract increased, and the IC ₅₀ (50% Inhibition concentration) value was 0.8%.

Experimental Example 6. Anti-allergic efficacy test

Figure 6 shows the anti-allergic effect of the sorrel extract of the present invention. The sorrel extract of Example 1 was prepared at 0.5 and 2.0% concentrations. In addition, 1 x 105 cells/well were dispensed per well in a 96-well plate, and then cultured in a 37°C, 5% CO2 incubator for 16 hours. The medium treated with monoclonal DNP-specific IgE (1 μg/mL) was allowed to react for 1 hour, then the medium was removed and washed using Tyrode's buffer (pH 7.3). Tyrode's buffer was dispensed into each well, incubated in an incubator at 37°C, 5% CO ₂ for 10 minutes, and Tyrode's buffer was removed.

Thereafter, after each treatment of the extract for each concentration and the sample without the extract for each concentration, the samples were incubated in a 37°C, 5% CO ₂ incubator for 20 minutes. DNP-BSA was treated and incubated for 2 hours in an incubator at 37°C, 5% CO ₂ . The supernatant was collected and mixed with p-nitrophenyl N-acetyl- ß-D-glucosamide at a ratio of 1:1 at 37°C and 5% CO _{2 .} After reacting in an incubator for 1 hour, each well was treated with sodium bicarbonate (pH 10.2), and the absorbance was measured at 405 nm and shown in FIG. 6 .

Referring to FIG. 6, it can be confirmed that the sorrel extract inhibits the induced β-hexosaminidase compared to the control, and in detail, exhibits an anti-allergic effect of 50.9% at a concentration of 2% (v/v).

Experimental Example 7. Antiviral efficacy test-1

Figure 7 shows the antiviral efficacy of the sorghum extract of the present invention. The novel coronavirus (SARS-CoV-2) can enter cells only when it binds to the ACE-2 receptor expressed on the surface of host cells. Therefore, it may provide antiviral efficacy if it inhibits the binding force of the ACE-2 receptor and the coronavirus.

First, 1 μg / mL SARS-CoV-2 Spike S1 Protein was dispensed in a 96-white well plate, and then attached in a 4 ° C incubator for 24 hours, and blocking buffer was dispensed and reacted while shaking at room temperature for 1 hour. 1%, 10%, and 100% of the extract, 1X Immuno buffer, and ACE2-His were dispensed into wells, respectively, and reacted with slow shaking at room temperature for 1 hour. After that, blocking buffer was dispensed and reacted while shaking at room temperature for 10 minutes, and Anti-His-HRP was reacted at room temperature for 1 hour while shaking slowly. ELISA ECL substrate A: ELISA ECL substrate B were mixed and dispensed at a ratio of 1:1, and immediately, luminescence was measured with a luminometer, as shown in FIG. 7 .

Referring to FIG. 7, as the concentration of the raspberry extract increases, the ability to inhibit the binding force between the coronavirus and the ACE-2 receptor increases. It can be confirmed that silver 100% inhibits the binding force of the two materials. Therefore, the antiviral efficacy of the sorrel extract of the present invention can be confirmed.

Experimental Example 8. Antiviral efficacy test-2

Figure 8 shows the antiviral efficacy of the sorrel extract of the present invention. 1.2×10 ⁵ cells/well were dispensed per well in a 384-well plate, and then cultured in a 37° C., 5% CO 2 incubator for 24 hours. Samples were treated by concentration and cultured in a 37°C, 5% CO ₂ incubator for 1 hour, and then SARS-CoV-2 (0.0125 MOI)-treated medium was dispensed and cultured in a 37°C, 5% CO 2 incubator for 24 hours. infected with it.

Thereafter, the cells were fixed with 4% paraformaldehyde and permeabilized. Thereafter, cells were stained with anti-SARS-CoV-2 nucleocapsid (N) primary antibody, Alexa Fluor 488-conjugated goat anti-rabbit IgG secondary antibody and Hoechst 33342. Fluorescent images of the infected cells were obtained using Operetta, a large-capacity image analysis device, and are shown in FIG. 8 .

In the acquired images, the total number of cells per well was calculated as the number of nuclei stained with hoechst, and the number of infected cells was calculated as the number of cells expressing the viral N protein/total number of cells. Infectivity was obtained by normalizing the average infectivity of wells containing uninfected cells and the average infectivity of wells containing infected cells treated with the sample solvent.

Referring to FIG. 8, it was confirmed that the activity of inhibiting SARS-CoV-2 infection increased as the concentration of the raspberry extract increased, and the IC ₅₀ (50% Inhibition Concentration) value was 31.12 μg/mL.

In this specification, preferred embodiments of the present invention have been disclosed, and although specific terms have been used, they are only used in a general sense to easily explain the technical details of the present invention and help understanding of the present invention, and do not limit the scope of the present invention. It is not meant to be limiting. It is obvious to those skilled in the art that other modifications based on the technical idea of the present invention can be implemented in addition to the embodiments disclosed herein.

Those of ordinary skill in the art will understand that various substitutions, changes, and modifications can be made without departing from the technical spirit of the present invention. Therefore, the scope of the invention should not be determined by the described embodiments, but by the technical idea described in the claims.

Claims (10)

An antiviral pharmaceutical composition comprising an extract of CURLED DOCK as an active ingredient. According to claim 1,
The antiviral pharmaceutical composition, characterized in that the sorrel extract is contained in 1 to 15% by weight relative to the total pharmaceutical composition. According to claim 1,
The prickly pear extract is extracted by using a porcupine root as a solvent with a combination ratio of at least one of water and alcohol, and the solvent is included in 85 to 99% by weight with respect to the entire pharmaceutical composition Antiviral pharmaceuticals, characterized in that enemy composition. According to claim 3,
The alcohol is an antiviral pharmaceutical composition, characterized in that it comprises any one or more of butylene glycol, ethylene glycol, propylene glycol, and glycerin. According to claim 1,
The virus is a pharmaceutical composition for antiviral, characterized in that the coronavirus (SARS-CoV-2). According to claim 1,
The sorrel extract is an antiviral pharmaceutical composition, characterized in that it exhibits antiviral activity by inhibiting the binding of coronavirus (SARS-CoV-2) with the ACE-2 receptor expressed on the surface of its host cell. An antiviral pharmaceutical external skin preparation containing CURLED DOCK extract as an active ingredient. An antiviral health functional food composition comprising an extract of CURLED DOCK as an active ingredient. A quasi-drug composition for preventing virus attachment, containing an extract of CURLED DOCK as an active ingredient. An antiviral cosmetic composition comprising an extract of CURLED DOCK as an active ingredient.